{"product_id":"sandoz-business-model-canvas","title":"Sandoz Group Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas: Strategic Blueprint for Generics and Biosimilars Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Sandoz Group's business model. This concise Business Model Canvas maps value propositions, key partners, channels, and revenue levers that drive scale in generics and biosimilars. Ideal for investors, consultants and founders—download the full Canvas in Word\/Excel to apply these insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI suppliers \u0026amp; CMOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024, Sandoz secures cost-effective, compliant inputs through strategic sourcing from qualified API manufacturers and CMOs, using multi-sourcing to reduce supply risk and price volatility. Long-term agreements lock in quality, volumes and continuity. Joint tech transfers with partners accelerate site readiness and scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech \u0026amp; research alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic biotech and research alliances secure biosimilar targets, proprietary cell lines, and advanced analytical platforms to accelerate development and comparability for regulatory filings.\u003c\/p\u003e\n\u003cp\u003eCo-development partnerships distribute R\u0026amp;D cost and technical risk across complex programs, enabling Sandoz to pursue multiple indications simultaneously.\u003c\/p\u003e\n\u003cp\u003eShared data and access to novel process technologies improve yields, strengthen regulatory packages, and shorten time-to-market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulators \u0026amp; standards bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eActive engagement with EMA, FDA and WHO accelerates approvals and regulatory clarity; by 2024 regulators had approved over 50 biosimilars in the US and 80+ in Europe, underpinning market access. Scientific advice from agencies de‑risks study designs and comparability exercises, lowering late‑stage failure risk. Close compliance collaboration improves inspection outcomes and audit readiness. Participation in policy forums drives biosimilar adoption and reimbursement reform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistributors \u0026amp; wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTier-1 wholesalers and logistics partners expand Sandoz reach to pharmacies and hospitals across 100+ countries in 2024; service-level agreements sustain fill rates and cold-chain integrity for temperature-sensitive generics and biosimilars. Data-sharing drives demand planning and tender readiness, while co-marketing programs support launches and therapy switches.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTier-1 distribution\u003c\/li\u003e\n\u003cli\u003eSLA: fill \u0026amp; cold-chain\u003c\/li\u003e\n\u003cli\u003eData-sharing for tenders\u003c\/li\u003e\n\u003cli\u003eCo-marketing for launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals, payers \u0026amp; tender agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFramework agreements with hospitals, payers and tender agencies secure multi-year volumes and market access, supporting Sandoz in a global generic medicines market valued at about $380 billion in 2024. Value-based arrangements tie price to outcomes and adherence, reducing total cost of care and enabling shared savings. Early stakeholder dialogue improves formulary inclusion; real-world evidence partnerships demonstrate therapeutic equivalence and measurable savings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-year contracts: 2–5 year tenders\u003c\/li\u003e\n\u003cli\u003e2024 market: ~$380B\u003c\/li\u003e\n\u003cli\u003eValue-based: price linked to outcomes\u003c\/li\u003e\n\u003cli\u003eRWE: proves equivalence and cost savings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term API partnerships and biotech co-development scale supply to \u003cstrong\u003e100+\u003c\/strong\u003e countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz leverages long‑term API\/CMO contracts, multi‑sourcing and tech transfers to secure supply, control cost and accelerate scale‑up. Biotech alliances and co‑development spread R\u0026amp;D risk and speed biosimilar filing; regulators and scientific advice de‑risk approvals. Tier‑1 wholesalers, logistics and payer\/hospital tenders enable reach across 100+ countries and multi‑year volumes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/CMO\u003c\/td\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003ctd\u003e100+ suppliers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulators\u003c\/td\u003e\n\u003ctd\u003eApprovals\u003c\/td\u003e\n\u003ctd\u003e50+ US, 80+ EU biosimilars\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Payers\u003c\/td\u003e\n\u003ctd\u003eTenders\u003c\/td\u003e\n\u003ctd\u003e2–5 yr contracts; $380B market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Sandoz Group mapping value propositions, customer segments, channels, revenue streams and key activities across the 9 BMC blocks, reflecting real-world operations and competitive advantages; includes SWOT-linked insights and a polished layout ideal for presentations, investor discussions and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Sandoz Group’s business model with editable cells—quickly identify core components like generics, biosimilars, and supply-chain levers to streamline decision-making and cut hours of strategic analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric \u0026amp; biosimilar R\u0026amp;D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeveloping robust formulations and comprehensive bioequivalence and comparability packages is core to Sandoz R\u0026amp;D, ensuring regulatory-ready dossiers and reliable product performance. Deep analytical characterization and process development reduce filing risk and manufacturing variability. Clinical PK\/PD studies establish biosimilarity, while ongoing lifecycle management—process improvements, indications, and cost optimization—sustains post-launch competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality-driven manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRunning GMP plants for small molecules, injectables and biologics ensures regulatory-compliant supply continuity; biologics typically require cold-chain storage at 2–8°C. Tech transfer, scale-up and validation follow FDA\/EMA GMP guidelines to control cost and quality. Continuous improvement programs raise yield and overall equipment effectiveness, while ISO 5\/7 sterile operations protect product sterility and integrity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; IP management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal dossier preparation, submissions and variations drive Sandoz market entry across \u0026gt;100 markets, with coordinated filings to meet EMA and FDA timelines; in 2024 EU FMD and US DSCSA serialization and traceability requirements remained enforced. Patent landscaping and targeted Paragraph IV\/UPC strategies time launches to patent expiries and litigation windows. Pharmacovigilance operations monitor safety and regulatory compliance across the portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTendering \u0026amp; market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTendering \u0026amp; market access focus on competitive pricing and health-economics dossiers to drive tender bids and win volume in key markets in 2024, leveraging demonstrated biosimilar cost-per-QALY analyses to support formulary inclusion.\u003c\/p\u003e\n\u003cp\u003eStakeholder education programs target physicians and payers to accelerate biosimilar uptake and switching, while contracting balances market share, rebates, and service levels.\u003c\/p\u003e\n\u003cp\u003eReimbursement navigation and local HTA engagement shorten time-to-adoption and improve tender success rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: health-economics dossiers for key biosimilars\u003c\/li\u003e\n\u003cli\u003eStakeholder education → higher switching\u003c\/li\u003e\n\u003cli\u003eContracts: share + rebates + service SLAs\u003c\/li\u003e\n\u003cli\u003eActive reimbursement\/HTA engagement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDemand forecasting and S\u0026amp;OP align production with tenders to secure supply for global procurement cycles; inventory management and GDP cold-chain logistics maintain availability across more than 100 markets in 2024; risk mitigation spreads production across multiple sites and suppliers to limit single-source failures; order-to-cash excellence preserves service levels and working capital. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDemand forecasting: S\u0026amp;OP tuned to tenders\u003c\/li\u003e\n\u003cli\u003eInventory \u0026amp; cold-chain: GDP-compliant global storage\u003c\/li\u003e\n\u003cli\u003eRisk mitigation: multi-site, multi-supplier\u003c\/li\u003e\n\u003cli\u003eOrder-to-cash: service continuity, cash focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated R\u0026amp;D, GMP manufacturing and global filings align supply to \u0026gt;100 markets in 2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D delivers regulatory-ready formulations, PK\/PD biosimilarity packages and lifecycle cost optimization. GMP manufacturing for small molecules, injectables and biologics (cold-chain 2–8°C) supports supply to \u0026gt;100 markets. Global filings, pharmacovigilance, tendering, HTA engagement and S\u0026amp;OP align launches and tender-driven supply in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain\u003c\/td\u003e\n\u003ctd\u003e2–8°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eEMA\/FDA coordinated filings\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the exact Sandoz Group Business Model Canvas you’ll receive—no mockup, no filler. Upon purchase you’ll instantly download the full, editable file formatted exactly as shown, ready for presentation and analysis. The deliverable includes both Word and Excel versions for seamless use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of 2024 Sandoz operates more than 20 manufacturing sites worldwide for APIs, oral solids, injectables and biologics, delivering industrial scale. Redundancy across sites enhances supply resilience and reduces single‑point failure risk. Advanced automation and aseptic assets lower unit costs and raise quality standards. Geographic proximity to key markets shortens lead times and improves responsiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific \u0026amp; regulatory talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced chemists, bioprocess engineers and clinicians at Sandoz—part of a ~25,000-strong global workforce in 2024—drive development from lead optimisation to clinical proof-of-concept. Regulatory affairs teams navigate FDA, EMA and 100+ market pathways to support high-volume filings. QA\/QC expertise enforces compliance across sites, while program managers keep programs on time and within budget.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP, dossiers \u0026amp; data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eComprehensive CTDs, analytical libraries and stability data enable accelerated filings and robust comparability packages that protect launches in markets where generics account for ~90% of prescriptions as of 2024. Process, formulation and comparability know-how form a technical moat reducing risk and cost of scale-up. Freedom-to-operate analyses time launches; real-world evidence programs drive faster uptake and payer acceptance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier \u0026amp; customer networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eApproved vendor lists secure quality inputs and regulatory compliance for generics and biosimilars. Deep relationships with wholesalers, hospitals and payers provide channel access and pricing leverage across more than 100 countries (2024). Tender pipelines and partnership frameworks deliver predictable demand and accelerate market entry for new products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eApproved vendors: quality \u0026amp; compliance\u003c\/li\u003e\n\u003cli\u003eWholesale\/hospital\/payer networks: market access\u003c\/li\u003e\n\u003cli\u003eTenders: predictable demand\u003c\/li\u003e\n\u003cli\u003ePartnerships: faster entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand trust \u0026amp; reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSandoz's long record of manufacturing quality and on-time supply underpins bids and contracts, supported by a 2024 global footprint of about 25,000 employees and operations in over 100 countries.\u003c\/p\u003e\n\u003cp\u003eClinician confidence drives biosimilar switching—WHO\/EMA data show biosimilars can cut treatment costs by roughly 30–50%—while patient trust improves adherence and outcomes, with some studies reporting adherence gains near 20%.\u003c\/p\u003e\n\u003cp\u003eCredibility eases regulatory and payer scrutiny, sustaining formulary access and tender success in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eemployees: ~25,000\u003c\/li\u003e\n\u003cli\u003emarkets: \u0026gt;100 countries\u003c\/li\u003e\n\u003cli\u003ebiosimilar cost reduction: 30–50%\u003c\/li\u003e\n\u003cli\u003eadherence uplift: ~20%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal biosimilars scale: ~25,000 staff, \u0026gt;20 plants, \u0026gt;100 markets, 30–50% cost cuts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSandoz key resources: ~25,000 employees, \u0026gt;20 global manufacturing sites, operations in \u0026gt;100 countries (2024); deep regulatory\/CTD libraries and QA\/QC teams enabling accelerated filings; approved vendor network and payer\/wholesale relationships securing supply and tenders; biosimilar expertise delivering 30–50% cost reductions and ~20% adherence uplift.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003ctd\u003e~25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar cost reduction\u003c\/td\u003e\n\u003ctd\u003e30–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence uplift\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAffordable essential medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompetitive pricing expands access: generics account for about 90% of dispensed prescriptions in the US and saved roughly $2.4 trillion for the US healthcare system over the last decade, lowering system costs. Generics and biosimilars (RAND estimated up to $54 billion US savings 2021–25) materially reduce therapy costs, freeing budgets for innovative treatments. Predictable supply through scaled manufacturing minimizes shortages and maintains continuity of care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh quality \u0026amp; regulatory rigor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompliance with global GMP and stringent testing assures product safety and supported Sandoz reported group sales of about $8.9 billion in 2023, reinforcing investment in quality controls. Robust comparability data builds clinician confidence and underpins market access for biosimilars. Consistent performance reduces therapeutic risk, while audit-ready systems and \u0026gt;100 regulatory audits annually minimize supply disruptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroad therapeutic coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBroad therapeutic coverage across CV, CNS, pain, oncology, respiratory and anti-infectives simplifies sourcing and supports customers in over 100 countries; generics represent about 90% of prescriptions in the US, underscoring demand. One-stop contracting reduces administrative burden and procurement cycles. Standardized packs and SKUs streamline operations and inventory. Regular portfolio refreshes sustain market relevance and price competitiveness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable global supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMulti-site manufacturing and diversified sourcing reduce shortage risk; in 2024 Sandoz sustained broad regional capacity and cold-chain plus sterile fill\/finish lines to protect injectables and biologic generics, maintaining industry-leading fill rates and deploying crisis response teams for surge capacity and recalls.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003e2024: multi-site, diversified sourcing\u003c\/li\u003e\n\u003cli\u003eCold-chain \u0026amp; sterile capabilities secured critical products\u003c\/li\u003e\n\u003cli\u003eHigh fill rates preserved supply\u003c\/li\u003e\n\u003cli\u003eCrisis teams handled surges\/recalls\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnering for outcomes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartnering for outcomes leverages HEOR and switching support to demonstrate cost-effective alternatives, enabling payer and provider savings while aligning with value-based contracts; generics now account for about 90% of U.S. prescriptions, underscoring substitution potential. Education and robust pharmacovigilance reduce unsafe use and support adherence. Co-created access programs target underserved populations amid WHO estimates that 2 billion people lack access to essential medicines; data-sharing drives policy and practice change.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHEOR\/switching: supports value-based savings\u003c\/li\u003e\n\u003cli\u003eEducation\/PV: lowers risk, improves adherence\u003c\/li\u003e\n\u003cli\u003eAccess programs: extend reach to underserved (WHO: 2B without essential meds)\u003c\/li\u003e\n\u003cli\u003eData-sharing: informs policy, enables scalable impact\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars and scale manufacturing cut costs, boost access and clinician confidence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive pricing and biosimilars drive cost savings and access, supporting continuity of care via scaled multi-site manufacturing and high fill rates. Rigorous GMP, \u0026gt;100 annual audits and robust comparability data secure market access and clinician confidence. HEOR, switching support and access programs extend reach to underserved populations.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2023\/24)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003eUSD 8.9B (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS prescriptions generics\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRAND biosimilar savings\u003c\/td\u003e\n\u003ctd\u003eup to USD 54B (2021–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeople lacking essentials\u003c\/td\u003e\n\u003ctd\u003eWHO: 2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 ops\u003c\/td\u003e\n\u003ctd\u003emulti-site capacity, high fill rates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic account management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDedicated strategic account teams serve wholesalers, GPOs and hospital chains across 100+ countries; they build joint business plans to align volumes, pricing and service levels. Regular monthly reviews track KPIs (fill rates, lead times, OTIF) and resolve supply or quality issues. Executive sponsorship from senior leadership deepens collaboration and accelerates escalation and investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical \u0026amp; medical support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedical affairs drives clinician education on biosimilarity and switching while scientific exchange focuses on comparability and immunogenicity data; continuous safety reporting and 24\/7 pharmacovigilance build trust (regulatory landscape: 40+ FDA biosimilar approvals by 2024), and advisory boards steer evidence needs, supporting over 100 global post‑marketing\/RWE studies in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContractual \u0026amp; tender-based ties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMulti-year tenders (commonly 2–5 years) and rebate frameworks secure stable procurement ties and predictable volumes; Sandoz operates in over 100 countries, leveraging scale. SLAs define fill rates (typical targets \u0026gt;95%), lead times and quality standards. Transparent pricing models foster long-term cooperation, while regular performance reporting sustains credibility with payers and distributors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital self-service portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDigital self-service portals enable online ordering with real-time inventory visibility and tracking, streamlining operations and reducing manual interventions. EDI integration cuts order errors by up to 50% and shortens cycle time by ~30%. Automated alerts reduce stockouts by ~20%, while analytics boost demand-forecast accuracy by 20–30% (2024 industry benchmarks).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline ordering: real-time inventory \u0026amp; tracking\u003c\/li\u003e\n\u003cli\u003eEDI: ~50% fewer errors, ~30% faster cycles\u003c\/li\u003e\n\u003cli\u003eAutomated alerts: ~20% fewer stockouts\u003c\/li\u003e\n\u003cli\u003eAnalytics: 20–30% better forecast accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and payer engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient and payer engagement emphasizes switching guides and adherence tools that support outcomes, while payer dialogue focuses on aligning on value and budget impact; Sandoz operates in more than 100 countries as of 2024, facilitating broad payer engagement. Pharmacovigilance channels remain accessible 24\/7 and multilingual materials broaden reach to diverse patient populations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eswitching guides → support outcomes\u003c\/li\u003e\n\u003cli\u003eadherence tools → improve persistence\u003c\/li\u003e\n\u003cli\u003epayer dialogue → align value \u0026amp; budget\u003c\/li\u003e\n\u003cli\u003epv channels → accessible 24\/7\u003c\/li\u003e\n\u003cli\u003emultilingual materials → global reach (100+ countries, 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccount teams keep \u003cstrong\u003e\u0026gt;95%\u003c\/strong\u003e fill rates in \u003cstrong\u003e100+\u003c\/strong\u003e countries; analytics cut stockouts \u003cstrong\u003e~20%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAccount teams serve wholesalers, GPOs and hospitals in 100+ countries, using monthly KPI reviews and exec sponsorship to maintain \u0026gt;95% fill rates. Medical affairs supports clinicians (40+ FDA biosimilars by 2024) and 100+ RWE studies (2024). Digital portals, EDI (~50% fewer errors) and analytics (+20–30% forecast accuracy) cut stockouts ~20%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFill rate target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA biosimilars\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRWE studies\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDI impact\u003c\/td\u003e\n\u003ctd\u003e-50% errors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecast gain\u003c\/td\u003e\n\u003ctd\u003e+20–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers \u0026amp; distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWholesalers and distributors are Sandozs primary route to retail and hospital pharmacies at scale, reaching over 100 countries. Consolidated logistics hubs lower cost-to-serve through pooled inventory and larger shipments. Regional service centers manage replenishment cadence and SKU flow. Real-time data feeds from distributors enable demand shaping and more accurate forecast-led stocking decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-hospital tenders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContracting directly with hospitals secures predictable institutional demand and supports volume planning for generics and biosimilars. Bundled lots and defined delivery windows align with hospital inventory cycles and surgical schedules, reducing stockouts. On-site technical and clinical support smooth formulary transitions and drive uptake. Performance KPIs such as on-time-in-full, fill rate and complaint rate are monitored to assure service levels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail \u0026amp; specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlacement in retail pharmacies drives patient access for chronic therapies, with 90% of patients living within close proximity to a community pharmacy (NACDS 2024), enabling adherence initiatives and scale. Specialty channels manage complex biologics and cold-chain logistics, reflecting specialty medicines accounting for about 48% of global medicine spend in 2024 (IQVIA). Co-pay support programs integrate where permitted to lower out-of-pocket costs, while targeted pharmacy education programs facilitate safe switches and adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment \u0026amp; NGO programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eParticipation in public procurement expands Sandoz reach in emerging markets where the public sector supplies roughly 60% of medicines; winning tenders in 2024 drove volume growth and market entry. WHO-prequalified Sandoz products qualify for global health initiatives, enabling institutional contracts and donor-funded programs. Multi-year volume commitments in tenders stabilize production planning and support cost-efficient manufacturing, while tiered pricing in 2024 preserved margins and improved affordability.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic procurement ~60% of medicines in low-income markets (2024)\u003c\/li\u003e\n\u003cli\u003eWHO prequalification enables donor-funded tenders\u003c\/li\u003e\n\u003cli\u003eVolume commitments reduce unit costs\u003c\/li\u003e\n\u003cli\u003eTiered pricing increases access while protecting revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital B2B platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital B2B platforms at Sandoz streamline orders and invoicing via portals and EDI, improving order fill through real-time availability and reducing backorders. Tight ERP integration enhances data accuracy and financial reconciliation, while self-service tools lower customer support volumes and speed fulfillment.  \n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003ePortals + EDI\u003c\/li\u003e\n\u003cli\u003eReal-time stock\u003c\/li\u003e\n\u003cli\u003eERP sync\u003c\/li\u003e\n\u003cli\u003eSelf-service\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDistribution in \u003cstrong\u003e100+\u003c\/strong\u003e countries; retail \u003cstrong\u003e90%\u003c\/strong\u003e proximity; specialty \u003cstrong\u003e48%\u003c\/strong\u003e spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eWholesalers\/distributors reach 100+ countries, central hubs cut cost-to-serve and enable pooled inventory. Direct hospital contracts secure predictable volumes for generics\/biosimilars; on-time-in-full and fill rate tracked. Retail pharmacies (90% patient proximity, NACDS 2024) and specialty channels (48% global spend 2024) handle adherence and cold-chain. Public procurement (~60% in low-income markets, 2024) and WHO prequalification expand tenders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003e2024 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e100+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty\u003c\/td\u003e\n\u003ctd\u003e48% global spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e90% patient proximity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic tenders\u003c\/td\u003e\n\u003ctd\u003e~60% low-income market supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals \u0026amp; health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals \u0026amp; health systems are high-volume users of injectables, oncology agents and anti-infectives, and in 2024 procurement continued to prioritize reliable supply, quality and tender-driven value.\u003c\/p\u003e\n\u003cp\u003eClinical evidence and real-world data increasingly determine P\u0026amp;T decisions, with hospitals demanding head-to-head data and pharmacoeconomic analyses.\u003c\/p\u003e\n\u003cp\u003eService levels—delivery reliability, cold chain integrity and dedicated account support—remain critical to contract retention and switching costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesalers \u0026amp; GPOs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWholesalers and GPOs aggregate demand to negotiate pricing and represent ≈80% of US hospital purchasing, amplifying leverage for volume discounts. They value consistent supply and product breadth to avoid stockouts and service penalties. Data-driven collaboration can improve forecasting accuracy by up to 20%, enhancing inventory turns. Compliance and serialization (EU FMD, US DSCSA) are mandatory across major markets by 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail \u0026amp; specialty pharmacies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail and specialty pharmacies dispense the bulk of chronic therapies and biologics, with specialty drugs accounting for roughly 55% of US drug spend in 2024. They require predictable inventory and integrated patient-support programs to manage adherence and provider coordination. Tight margin structures driven by payer contracts force competitive pricing and rebate management. Clear, regulator-compliant education materials are essential to effective patient counseling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; government agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayers and government agencies set formulary and reimbursement rules, prioritizing cost containment and measurable outcomes; biosimilars are preferred where evidence shows savings and therapeutic equivalence. Payers report biosimilars reduce biologic costs by roughly 30–60% and have contributed an estimated $250 billion in cumulative system savings through 2024 (IQVIA 2024). Robust post‑market safety surveillance and real‑world evidence are required for coverage decisions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrive formulary \u0026amp; reimbursement\u003c\/li\u003e\n\u003cli\u003ePrioritize cost containment \u0026amp; outcomes\u003c\/li\u003e\n\u003cli\u003eFavor proven biosimilar savings (~30–60%, ≈$250B 2014–2024)\u003c\/li\u003e\n\u003cli\u003eRequire robust safety surveillance \u0026amp; RWE\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinicians \u0026amp; patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinicians and patients are the end users whose confidence drives Sandoz adoption; clear information and support improve prescribing and adherence, with long‑term therapy adherence averaging about 50% for chronic conditions (WHO). They rely on continuity of therapy and benefit from Sandoz affordability and access programs that reduce cost-related interruptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEnd users: clinicians, patients\u003c\/li\u003e\n\u003cli\u003eTrust \u0026amp; info: critical for uptake\u003c\/li\u003e\n\u003cli\u003eContinuity: adherence ~50% (chronic therapy)\u003c\/li\u003e\n\u003cli\u003eAccess: affordability programs reduce interruptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and payers push biosimilars \u003cstrong\u003e30-60%\u003c\/strong\u003e savings; supply, access, adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHospitals \u0026amp; health systems prioritize reliable supply, quality and tender-driven value; wholesalers\/GPOs drive ≈80% of US hospital purchasing (2024).\u003c\/p\u003e\n\u003cp\u003eRetail\/specialty pharmacies manage chronic\/biologic dispensing; specialty drugs ≈55% of US drug spend (2024).\u003c\/p\u003e\n\u003cp\u003ePayers favor biosimilars (30–60% price reduction), contributing ≈$250B system savings 2014–2024; RWE and safety surveillance required.\u003c\/p\u003e\n\u003cp\u003eClinician\/patient trust and adherence (~50% chronic) hinge on continuity and access programs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey 2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/Wholesalers\u003c\/td\u003e\n\u003ctd\u003e≈80% US hospital purchasing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\/Specialty\u003c\/td\u003e\n\u003ctd\u003e55% US drug spend\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003e30–60% biosimilar savings; $250B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\/Clinicians\u003c\/td\u003e\n\u003ctd\u003eAdherence ~50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing \u0026amp; COGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAPIs, excipients, utilities and labor drive roughly 60-80% of COGS for Sandoz generics, with APIs often the single largest line. Biologics require 2-3x higher fixed sterile and cold-chain spend versus small molecules, raising capex and OPEX materially. Yield and OEE (commonly 60-75%) directly alter unit economics, where each 1% yield gain can cut unit COGS ~1-2%. Validation and maintenance typically add about 5-10% to annual manufacturing costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D and clinical programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D and clinical programs drive major cost lines: analytical characterization and trials for biosimilars require high-capacity labs and long timelines, while formulation and BE studies for generics add scale efficiencies; device and drug–device combination work increases complexity and CAPEX, and ongoing post-market studies in 2024 sustain regulatory trust and product uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; quality compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInspections, audits and QMS operations are recurring cost drivers, with Sandoz sites facing hundreds of regulatory and GMP inspections annually across markets. Serialization, track-and-trace and pharmacovigilance programs add ongoing overhead and technology spend; industry estimates put PV and serialization budgets in the low-single-digit percent range of pharma operating costs. Documentation, dossier submissions and translations consume significant headcount and consultancy resources. Remediation reserves are maintained to mitigate inspection-related risk and potential recall costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales, marketing \u0026amp; access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTendering teams, HEOR and medical education drive product uptake through value dossiers and clinician outreach, while contract rebates and chargebacks materially reduce net pricing and margin. Digital platforms and CRM streamline targeting and reduce field costs; training and switch materials lower prescribing friction and support formulary wins. Costs concentrate on rebate provisions, digital and training investments and tender management.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTendering teams: bid preparation, account management\u003c\/li\u003e\n\u003cli\u003eHEOR \u0026amp; medical education: value evidence and clinician engagement\u003c\/li\u003e\n\u003cli\u003eNet pricing: contract rebates and chargebacks impact margins\u003c\/li\u003e\n\u003cli\u003eDigital\/CRM: efficiency and cost reduction\u003c\/li\u003e\n\u003cli\u003eTraining\/materials: support switching and uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics \u0026amp; distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLogistics and distribution for Sandoz hinge on warehousing, cold-chain handling, and transport, driving a large share of operating cost and service risk. Maintaining safety stock ties up working capital and inflates inventory carrying costs. Freight volatility compresses margins and requires dynamic routing and hedging. Robust reverse logistics and recall protocols are essential to protect brand and patient safety.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWarehousing: high fixed costs, temperature control needs\u003c\/li\u003e\n\u003cli\u003eCold-chain: critical for biologics, strict compliance\u003c\/li\u003e\n\u003cli\u003eSafety stock: capital tied, impacts liquidity\u003c\/li\u003e\n\u003cli\u003eFreight volatility: margin pressure, requires hedging\u003c\/li\u003e\n\u003cli\u003eReverse logistics: recall readiness, traceability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPIs\/utilities\/labor = \u003cstrong\u003e60-80%\u003c\/strong\u003e COGS; biologics \u003cstrong\u003e2-3x\u003c\/strong\u003e more\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAPIs\/excipients, utilities and labor drive ~60–80% of COGS for Sandoz generics; biologics incur ~2–3x higher sterile\/cold-chain capex and OPEX. OEE\/yield (typically 60–75%) meaningfully shifts unit COGS (each 1% yield ≈1–2% COGS change); validation\/maintenance add ~5–10% annually. PV\/serialization and compliance consume low-single-digit percent of operating costs; inspections number in the hundreds annually.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003enote\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPIs\/COGS\u003c\/td\u003e\n\u003ctd\u003e60–80%\u003c\/td\u003e\n\u003ctd\u003elargest line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics spend\u003c\/td\u003e\n\u003ctd\u003e2–3x\u003c\/td\u003e\n\u003ctd\u003evs small molecules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEE\/yield\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003ctd\u003e±1% yield → ±1–2% COGS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation\u003c\/td\u003e\n\u003ctd\u003e5–10%\u003c\/td\u003e\n\u003ctd\u003eannual manuf. cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric pharmaceuticals sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from generics is volume-driven across oral solids and injectables, relying on high prescription volumes—generics account for about 90% of US prescriptions by volume (FDA 2024). Competes on price, quality and service; a broad portfolio secures shelf space and channel access, while lifecycle management (formulation updates, new strengths, biosimilar launches) protects market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilars revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBiosimilars revenue centers on higher-value oncology and immunology products with clinical and access support; the global biosimilars market reached about USD 30 billion in 2024, underscoring scale. Adoption tracks payer policies and clinician confidence, with market share gains accelerated by hospital switching programs. Multi-year supply and tender contracts provide recurring revenue that stabilizes cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAPI \u0026amp; third-party supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSales of active ingredients and contract manufacturing provide diversification by adding API and third-party supply revenues alongside finished-dose generics. Long-term supply agreements deliver multi-year revenue visibility and reduce demand volatility. Higher capacity utilization in manufacturing drives margin expansion, while Sandozs quality reputation and regulatory track record attract multinational clients and contract wins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTender \u0026amp; institutional contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMulti-year tender and institutional contracts anchor Sandoz volumes, securing baseline demand across hospitals and government programs.\u003c\/p\u003e\n\u003cp\u003ePrice-for-volume and rebate structures determine net sales realization while performance bonuses and penalties adjust final pricing based on delivery and quality metrics.\u003c\/p\u003e\n\u003cp\u003ePredictable contract cadence and renewal schedules make revenue highly forecastable, supporting production and cash-flow planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAnchors volumes: multi-year contracts\u003c\/li\u003e\n\u003cli\u003eNet sales: price-for-volume \u0026amp; rebates\u003c\/li\u003e\n\u003cli\u003eAdjustments: bonuses\/penalties\u003c\/li\u003e\n\u003cli\u003eBenefit: forecastable revenue for planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional \u0026amp; emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTiered pricing and public programs expand reach in emerging markets; IQVIA projects 2024 pharmaceutical growth in emerging markets at about 6%, supporting volume-based revenue. Currency volatility and shifting reimbursement policies materially shape net realization and margins. Portfolio localization and local manufacturing increase tender access while rising demand drives scale economies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTiered pricing: volume + access\u003c\/li\u003e\n\u003cli\u003eFX \u0026amp; policy: margin pressure\u003c\/li\u003e\n\u003cli\u003eLocalization: tender wins\u003c\/li\u003e\n\u003cli\u003eMarket growth: ~6% (IQVIA 2024)\u003c\/li\u003e\n\u003cli\u003ePublic procurement: ~40% generics volume (WHO 2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenerics volume-led, biosimilars and API contracts drive resilient pharma revenues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGenerics drive high-volume, low-margin sales (~90% of US Rx by volume, FDA 2024) with lifecycle management preserving share. Biosimilars are higher-value (global market ~USD 30B in 2024) and rely on access programs and tenders for recurring revenue. API\/CMO and multi-year contracts diversify cash flows; emerging markets growth ~6% (IQVIA 2024) and public procurement ~40% generics (WHO 2024) shape pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics\u003c\/td\u003e\n\u003ctd\u003e~90% US Rx vol\u003c\/td\u003e\n\u003ctd\u003eVolume-driven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilars\u003c\/td\u003e\n\u003ctd\u003eUSD 30B market\u003c\/td\u003e\n\u003ctd\u003eHigher margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPI\/CMO\u003c\/td\u003e\n\u003ctd\u003eMulti-year contracts\u003c\/td\u003e\n\u003ctd\u003eStability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58098210439516,"sku":"sandoz-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/sandoz-business-model-canvas.png?v=1781804994","url":"https:\/\/pestel-analysis.com\/products\/sandoz-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}